Regenerative Medicine

Promethera acquires Baliopharm

The Belgium-based cell therapy company Promethera Biosciences SA has branched out into biologics with the acquisition of Baliopharm AG, a Swiss developer of therapies for immune-mediated inflammatory diseases and cancer. Financial details of the transaction were not disclosed.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium

GSK gene therapy deal

Orchard Therapeutics Ltd has come closer to its goal of becoming a global supplier of gene therapies following an agreement with GlaxoSmithKline Plc to take over that company’s portfolio of gene therapies for rare diseases.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Novartis to acquire AveXis

Novartis appears set to become a first mover in gene therapy again with the agreed acquisition of AveXis Inc, a company with a late-stage gene replacement therapy for treating spinal muscular atrophy (SMA).

Location

Switzerland

Cellectis’ allogeneic portfolio gets boost

France-based Cellectis SA has acquired a new partner for its portfolio of products for cancer that are based on donor T cells that have been engineered to target specific antigen on cancer cells. The allogeneic portfolio had been licensed to Pfizer Inc and Servier.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France

Autolus files for potential US IPO

UK-based Autolus Ltd has made a submission to the US Securities and Exchange Commission relating to a potential initial public offering of its shares. As of 8 March, the timing and terms of the potential offering had not been determined.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Gilead gains rights to gene editing technology

A zinc finger nuclease gene editing technology is to be used to develop ex vivo cell therapies for cancer, under a new research collaboration between the Gilead Sciences company Kite and Sangamo Therapeutics Inc.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

Synpromics works with UCL

Synpromics Ltd is bringing its technology for creating synthetic promoters into a partnership with a unit of University College London (UCL) in order to help researchers there develop gene therapies for blood-based disorders. The agreement was announced on 25 January.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

New delivery for gene therapy

The prospect of being able to re-dose a gene therapy has come into the fore with the launch on 4 January of Generation Bio Inc, a company with technology for delivering DNA directly to the liver using lipid nanoparticles rather than a viral vector.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

Takeda to acquire cell therapy company TiGenix

Japan’s Takeda Pharmaceutical Company Ltd has announced plans to acquire the Belgium-based cell therapy company TiGenix NV for €520 million, a company with which it already has a licensing deal for the company’s lead product.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium

Spark offers outcomes-based rebates for gene therapy

Spark Therapeutics Inc has set the price per patient of its new gene therapy for retinal dystrophy at $850,000 but at the same time opened negotiations with leading US insurers to link payments with the success of the treatment.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

Syndicate content